
The advent of GLP-1 treatments has been a game changer in the medical sector for weight loss and chronic obesity. The GLP-1 market is currently dominated by semaglutide (Ozempic and Wegovy) produced by Novo Nordisk A/S (NYSE: NVO) and tirzepatide (Mounjaro and Zepbound) produced by Eli Lilly and Co. (NYSE: LLY). The once-a-week injections are still in short supply despite costing over $1,000 a month. Eli Lilly’s Mounjaro sales surged over 114% YoY in its Q3 2024.
However, health insurers are becoming more reluctant about coverage, and people with anxiety over needle injections are still staying away. Among all the new therapies in studies, a novel approach to weight loss utilizing ultrasound is being developed by Novo Nordisk and GE HealthCare Technologies Inc. (NASDAQ: GEHC).